Compare Gilead Sciences, Inc. (GILD) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Phillips 66 — how do they compare? Gilead Sciences, Inc. trades at $136.1 (market cap $163.51B), while Phillips 66 trades at $201.27 (market cap $78.65B). The key difference: Gilead Sciences, Inc. is far larger — about 2.1× Phillips 66's market cap, and Phillips 66 pays the higher dividend (2.59%). Which is the better fit depends on your goals.
| GILD | PSX | |
|---|---|---|
Market Cap | $163.51B | $78.65B |
Sector | Health | Energy |
52-Week High | $155.80 | $201.45 |
52-Week Low | $108.22 | $118.37 |
Enterprise Value | $178.05B | $100.62B |
Dividend Yield | 2.49% | 2.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Phillips 66 (PSX) trades at $201.86, up 0.2% on the day, with a bullish technical signal and strong analyst support. The stock shows robust earnings beats in recent quarters, including Q1 2026's surprise profit, while maintaining solid profitability metrics like a 14.75% ROE. Recent news highlights refining margin strength and dividend consistency, with two $1.27 payouts in 2026. Cash flow trends improved in 2025, though revenue has declined from 2022 peaks.
PSX offers value with a P/E of 19.38 and P/S of 0.59, supported by 57% analyst buy ratings and a $201.50 consensus target. Risks include volatile refining margins, debt levels at 27.18% of assets, and revenue contraction since 2022. The stock's proximity to its 52-week high suggests limited near-term upside without new catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
